Literature DB >> 27966558

Gene Therapy for Epidermolysis Bullosa: Sticky Business.

Alexander Nyström, Leena Bruckner-Tuderman.   

Abstract

Mesh：

Year:  2016        PMID： 27966558      PMCID： PMC5167791          DOI： 10.1038/mt.2016.199

Source DB:  PubMed          Journal:  Mol Ther        ISSN： 1525-0016            Impact factor:   11.454


× No keyword cloud information.
  15 in total

Review 1.  Molecular pathology of the basement membrane zone in heritable blistering diseases:: The paradigm of epidermolysis bullosa.

Authors:  Jouni Uitto; Cristina Has; Hassan Vahidnezhad; Leila Youssefian; Leena Bruckner-Tuderman
Journal:  Matrix Biol       Date:  2016-08-03       Impact factor: 11.583

2.  Analysis of the functional consequences of targeted exon deletion in COL7A1 reveals prospects for dystrophic epidermolysis bullosa therapy.

Authors:  Olivier Bornert; Tobias Kühl; Jeroen Bremer; Peter C van den Akker; Anna Mg Pasmooij; Alexander Nyström
Journal:  Mol Ther       Date:  2016-05-09       Impact factor: 11.454

Review 3.  Cell therapy for basement membrane-linked diseases.

Authors:  Alexander Nyström; Olivier Bornert; Tobias Kühl
Journal:  Matrix Biol       Date:  2016-09-05       Impact factor: 11.583

4.  Bone marrow transplantation for recessive dystrophic epidermolysis bullosa.

Authors:  John E Wagner; Akemi Ishida-Yamamoto; John A McGrath; Maria Hordinsky; Douglas R Keene; David T Woodley; Mei Chen; Megan J Riddle; Mark J Osborn; Troy Lund; Michelle Dolan; Bruce R Blazar; Jakub Tolar
Journal:  N Engl J Med       Date:  2010-08-12       Impact factor: 91.245

5.  A phase II randomized vehicle-controlled trial of intradermal allogeneic fibroblasts for recessive dystrophic epidermolysis bullosa.

Authors:  Supriya S Venugopal; Wenfei Yan; John W Frew; Heather I Cohn; Lesley M Rhodes; Kim Tran; Wei Melbourne; Janis A Nelson; Marian Sturm; Janice Fogarty; M Peter Marinkovich; Satomi Igawa; Akemi Ishida-Yamamoto; Dedee F Murrell
Journal:  J Am Acad Dermatol       Date:  2013-09-24       Impact factor: 11.527

6.  Revertant mosaicism in junctional epidermolysis bullosa due to multiple correcting second-site mutations in LAMB3.

Authors:  Anna M G Pasmooij; Hendri H Pas; Maria C Bolling; Marcel F Jonkman
Journal:  J Clin Invest       Date:  2007-05       Impact factor: 14.808

7.  Potential of fibroblast cell therapy for recessive dystrophic epidermolysis bullosa.

Authors:  Tracy Wong; Luke Gammon; Lu Liu; Jemima E Mellerio; Patricia J C Dopping-Hepenstal; John Pacy; George Elia; Rosemary Jeffery; Irene M Leigh; Harshad Navsaria; John A McGrath
Journal:  J Invest Dermatol       Date:  2008-04-03       Impact factor: 8.551

8.  Monozygotic twins discordant for recessive dystrophic epidermolysis bullosa phenotype highlight the role of TGF-β signalling in modifying disease severity.

Authors:  Teresa Odorisio; Michela Di Salvio; Angela Orecchia; Giovanni Di Zenzo; Eugenia Piccinni; Francesca Cianfarani; Antonella Travaglione; Paolo Uva; Barbara Bellei; Andrea Conti; Giovanna Zambruno; Daniele Castiglia
Journal:  Hum Mol Genet       Date:  2014-03-05       Impact factor: 6.150

9.  Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells.

Authors:  Fulvio Mavilio; Graziella Pellegrini; Stefano Ferrari; Francesca Di Nunzio; Enzo Di Iorio; Alessandra Recchia; Giulietta Maruggi; Giuliana Ferrari; Elena Provasi; Chiara Bonini; Sergio Capurro; Andrea Conti; Cristina Magnoni; Alberto Giannetti; Michele De Luca
Journal:  Nat Med       Date:  2006-11-19       Impact factor: 53.440

10.  Immunohistochemical and mutation analyses demonstrate that procollagen VII is processed to collagen VII through removal of the NC-2 domain.

Authors:  L Bruckner-Tuderman; O Nilssen; D R Zimmermann; M T Dours-Zimmermann; D U Kalinke; T Gedde-Dahl; J O Winberg
Journal:  J Cell Biol       Date:  1995-10       Impact factor: 10.539
View more
  6 in total

Review 1.  Toward Combined Cell and Gene Therapy for Genodermatoses.

Authors:  Laura De Rosa; Maria Carmela Latella; Alessia Secone Seconetti; Cecilia Cattelani; Johann W Bauer; Sergio Bondanza; Michele De Luca
Journal:  Cold Spring Harb Perspect Biol       Date:  2020-05-01       Impact factor: 10.005

Review 2.  Pathogenetic Therapy of Epidermolysis Bullosa: Current State and Prospects.

Authors:  I I Ryumina; K V Goryunov; D N Silachev; Yu A Shevtsova; V A Babenko; N M Marycheva; Yu Yu Kotalevskaya; V V Zubkov; G T Zubkov
Journal:  Bull Exp Biol Med       Date:  2021-05-29       Impact factor: 0.804

Review 3.  Recent advances in understanding and managing epidermolysis bullosa.

Authors:  Dimitra Kiritsi; Alexander Nyström
Journal:  F1000Res       Date:  2018-07-17

4.  Collagen VII Expression Is Required in Both Keratinocytes and Fibroblasts for Anchoring Fibril Formation in Bilayer Engineered Skin Substitutes.

Authors:  Dorothy M Supp; Jennifer M Hahn; Kelly A Combs; Kevin L McFarland; Ann Schwentker; Raymond E Boissy; Steven T Boyce; Heather M Powell; Anne W Lucky
Journal:  Cell Transplant       Date:  2019-07-04       Impact factor: 4.064

Review 5.  Baculoviruses in Gene Therapy and Personalized Medicine.

Authors:  Sabrina Schaly; Merry Ghebretatios; Satya Prakash
Journal:  Biologics       Date:  2021-04-28

Review 6.  Ex vivo gene modification therapy for genetic skin diseases-recent advances in gene modification technologies and delivery.

Authors:  Vignesh Jayarajan; Evangelia Kounatidou; Waseem Qasim; Wei-Li Di
Journal:  Exp Dermatol       Date:  2021-03-11       Impact factor: 3.960
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.